NeuroSense Therapeutics Starts HIPAA Compliance Process
Ticker: NRSNW · Form: 6-K · Filed: Sep 16, 2024 · CIK: 1875091
| Field | Detail |
|---|---|
| Company | Neurosense Therapeutics LTD. (NRSNW) |
| Form Type | 6-K |
| Filed Date | Sep 16, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-compliance, healthcare, data-privacy
TL;DR
NeuroSense is getting HIPAA compliant, big deal for patient data privacy.
AI Summary
NeuroSense Therapeutics Ltd. announced on September 16, 2024, that it has officially begun the process of complying with HIPAA regulations. This move is a significant step for the company in ensuring patient data privacy and security as it advances its pharmaceutical development.
Why It Matters
Compliance with HIPAA is crucial for healthcare companies to protect sensitive patient information, which is essential for clinical trials and future commercialization of their therapies.
Risk Assessment
Risk Level: low — This filing is an informational update regarding regulatory compliance and does not involve financial transactions or significant operational changes that would inherently increase risk.
Key Players & Entities
- NeuroSense Therapeutics Ltd. (company) — Filer of the report
- HIPAA (regulation) — Subject of compliance process
- September 16, 2024 (date) — Date of the announcement
FAQ
What is the primary purpose of this 6-K filing?
The primary purpose of this 6-K filing is to report that NeuroSense Therapeutics Ltd. has officially initiated the process to comply with HIPAA regulations.
When was this announcement made?
The announcement was made on September 16, 2024.
What specific regulations is NeuroSense Therapeutics Ltd. complying with?
NeuroSense Therapeutics Ltd. is initiating the process to comply with HIPAA (Health Insurance Portability and Accountability Act) regulations.
What is the company's principal executive office address?
The company's principal executive office is located at 11 HaMenofim Street, Building B, Herzliya 4672562, Israel.
Does NeuroSense Therapeutics file annual reports under Form 20-F or 40-F?
NeuroSense Therapeutics indicates it files annual reports under Form 20-F.
Filing Stats: 162 words · 1 min read · ~1 pages · Grade level 12.9 · Accepted 2024-09-16 06:10:57
Filing Documents
- ea0214621-6k_neurosense.htm (6-K) — 8KB
- 0001213900-24-078701.txt ( ) — 9KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NeuroSense Therapeutics Ltd. Date: September 16, 2024 By: /s/ Alon Ben-Noon Alon Ben-Noon Chief Executive Officer 2